Filing Flows › Biofrontera (BFRI) › Q1 2026
Biofrontera (BFRI) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Biofrontera (BFRI) reported revenue of $10.1M for the first quarter 2026 (Q1 2026), +17% from a year earlier and -41% from the quarter before. Operating margin was -42.8%, net loss $4.8M (47.1% of revenue).
Biofrontera, Q1 2026: revenue $10.1M (+17% year over year), operating margin -42.8%, net loss $4.8M, operating cash flow −$70K. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.1M | -41% | +17% |
| Operating profit | −$4.3M | -195% | — |
| Net earnings | −$4.8M | -184% | — |
| Operating cash flow | −$70K | — | — |
What changed
Revenue was $10.1M in Q1 2026, up 17% year over year and down 41% from the previous quarter.
Operating costs exceeded revenue by $4.3M, an operating margin of -42.8%. Total costs grew 10% against revenue growth of 17%. The fastest-growing cost line was SG&A (+27%). The quarter ended with a net loss of $4.8M, after a profit of $5.6M the previous quarter.
Operating cash flow was −$70K. Non-cash charges added back $55K of depreciation and amortization and $342K of share-based compensation. Working capital and other items added $4.3M. Capital expenditures of $5K exceeded it, leaving free cash flow of −$75K.
Questions
What was Biofrontera's revenue in the first quarter 2026?
Biofrontera (BFRI) reported revenue of $10.1M for the first quarter 2026 (Q1 2026), +17% from a year earlier and -41% from the quarter before.
Was Biofrontera profitable in the first quarter 2026?
Operating loss was $4.3M (-42.8% of revenue) and net loss $4.8M.
Source: Biofrontera 10-Q on SEC EDGAR.